Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed ...

Clinicians should adopt a risk-based, rather than biopsy-first, approach to encourage biopsy acceptance and improve early ...

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.

AUSTIN, TX & PHILADELPHIA, PA — Faeth Therapeutics and The GOG Foundation, Inc. have announced a significant milestone in the ...

Black women tend to get more aggressive uterine cancers than White women. But this is only part of the story, investigators ...

Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future.

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...

The following is a summary of “Facilitators and Barriers to Acceptability of a Biopsy-First Approach in the Diagnostic ...

Event to be held via webcast on March 25, 2025 at 4:00 p.m. ETTo highlight differentiated drug discovery capabilities with its Generative ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

H.C. Wainwright says that competitor data demonstrate impressive ORR in endometrial cancer, opening a potential opportunity for NetCure’s ...